<DOC>
	<DOCNO>NCT02646397</DOCNO>
	<brief_summary>The purpose study compare effect fosinopril plus benidipine vs. fosinopril plus hydrochlorothiazide renal function 6-month treatment CKD patient HTN .</brief_summary>
	<brief_title>Benidipine Hydrochlorothiazide Fosinopril Treated Chronic Kidney Disease Patients With Hypertension</brief_title>
	<detailed_description>Patients chronic kidney dysfunction injury affect health three month diagnose chronic kidney disease ( CKD ) .China high prevalence CKD.The prevalence , awareness , treatment hypertension ( HTN ) non-dialysis CKD patient 67.3 % ,85.8 % , 81.0 % , respectively . The renin-angiotensin system inhibitor ( RASI ) include angiotensin-converting enzyme inhibitor ( ACEI ) angiotensin II type 1 receptor blocker ( ARB ) deeply confirm apparent reno-protective effect patient CKD.Co-administration diuretic calcium channel blocker ( CCBs ) ACEIs ARBs common combination . Hydrochlorothiazide plus RASIs another widely use combination accord synergetic function antihypertensive action offset mutual adverse effect . Until , large scale study compare effect initial treatment two different combination antihypertensive drug CKD patient progression kidney disease China . Studies subsets CKD ( diabetes non-diabetes , micro-albuminuria macro-albuminuria ) urgently needed.We aim conduct large scale study compare L/T-type CCB diuretic basis ACEI CKD HTN renal progression CKD China .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Fosinopril</mesh_term>
	<mesh_term>Benidipine</mesh_term>
	<criteria>1 . Patients diagnose nondialysis CKD enrollment randomization eGFR≥ 30 ml/min per 1.73 m2 enrollment randomization SBP &gt; 130 mmHg and/or DBP &gt; 80 mmHg enrollment randomization . Patients could receive two antihypertensive medication prior enrollment , discontinue prior antihypertensive medication enrollment accord investigator ' advice . 2 . 24 h proteinuria &lt; 1.5g enrollment 3 . Patients sign informed consent form 4 . Baseline serum Cr &lt; 3 mg/dL enrollment randomization 1 . Hypertensive crisis ( SBP &gt; 180 mmHg and/or DBP &gt; 110 mmHg ) 2 . Refractory hypertension ( take &gt; 2 antihypertensive drug month , SBP still &gt; 160mm Hg DBP &gt; 100mmHg ) 3 . Baseline serum Cr &gt; 3 mg/dl , kidney transplantation 4 . Patients diagnose severe cardiac arrhythmia ( severe extra beat , supraventricular tachycardia , ventricular arrhythmia , bradyarrhythmias ) , heart failure , NYHA &gt; Ⅲ , angina , stroke , leave ventricular hypertrophy myocardial infarction within 12 month prior first visit . 5 . Patients diagnose cancer severe sepsis 6 . Hematological system disorder : myelodysplastic syndrome , granulocytopenia , hypereosinophilic syndrome , polycythemia , thrombocytopenia , et al . 7 . Restrictive pericarditis 8 . Systemic Lupus Erythematous 9 . Severe diabetes complication diabetic ketoacidosis , hyperosmolar coma , retinopathy , amputation , et al . 10 . Patients diagnose hyperkalemia ( &gt; 5.5mmol/L ) within 6 month enrollment 11 . Renal artery stenosis vascular embolism disease 12 . Patient currently pregnant lactational 13 . AST/ALT &gt; three time upper limit standard value baseline 14 . Any severe allergy CCB , diuretic ACE inhibitor 15 . History severe side effect CCB , diuretic ACE inhibitor ; longterm use nonsteroidal antiinflammatory drug 16 . Use investigational drug within 30 day 5 halflives last visit , whichever longer . 17 . Other unsuitable patient judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>glomerular filtration rate</keyword>
	<keyword>hypertension</keyword>
</DOC>